Suppr超能文献

治疗变应性鼻炎可降低 2-18 岁哮喘儿童急性哮喘加重风险。

Treatment of allergic rhinitis reduces acute asthma exacerbation risk among asthmatic children aged 2-18 years.

机构信息

Department of Pediatrics, Madou Sin-Lau Hospital, Tainan, Taiwan.

Clinical Medical Research Center, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi City 60002, Taiwan.

出版信息

J Microbiol Immunol Infect. 2019 Dec;52(6):991-999. doi: 10.1016/j.jmii.2018.10.003. Epub 2018 Oct 25.

Abstract

BACKGROUND/PURPOSE: Asthma and allergic rhinitis (AR) frequently coexist in the same individuals in childhood and adolescence. We evaluated whether AR had an impact on acute exacerbation (AE) and whether intranasal corticosteroid (INCS) and second-generation antihistamines (SGH) for AR modified the association of AR with AE in asthmatics aged 2-6 years and 7-18 years.

METHODS

Using the National Health Research Institutes (NHRI) Database 2005 of Taiwan, we investigated patients who had been diagnosed with asthma in the years 2000 through 2012 and who had then been followed-up with for at least one year. The risk factors of AE were evaluated using multiple Cox proportional hazards regression analysis.

RESULTS

The incidence of AE was higher in the preschool group than the older group (adj. HR: 1.68, 95% CI: 1.44-1.95). The AR with INCS and/or SGH group was found to have a lower risk of AE than the non-AR group (adj. HR: 0.32, 0.44 and 0.30), but the AR without treatment group did not have a significant difference with the non-AR group. After propensity score matching, the use of INCS and/or SGH was associated with a significant reduction in the occurrence of AE among AR patients aged 2-6 years old (adj. HR: 0.38, 0.57 and 0.45) and 7-18 years old (adj. HR: 0.50, 0.52 and 0.35).

CONCLUSION

The preschool patients had a higher incidence of AE than the older patients in general. Adequate treatment with INCS and/or SGH in asthma with AR patients is important for reducing the incidence of AE of asthma.

摘要

背景/目的:哮喘和过敏性鼻炎(AR)在儿童和青少年中经常同时存在。我们评估了 AR 是否会影响急性加重(AE),以及 AR 患者是否使用鼻内皮质类固醇(INCS)和第二代抗组胺药(SGH)治疗会改变 AR 与 2-6 岁和 7-18 岁哮喘患者 AE 的关联。

方法

利用台湾国家健康研究机构(NHRI)数据库 2005 年的数据,我们调查了 2000 年至 2012 年期间被诊断为哮喘且随访至少一年的患者。使用多 Cox 比例风险回归分析评估 AE 的危险因素。

结果

学龄前组的 AE 发生率高于年长组(调整后的 HR:1.68,95%CI:1.44-1.95)。使用 INCS 和/或 SGH 的 AR 组与非 AR 组相比,AE 的风险较低(调整后的 HR:0.32、0.44 和 0.30),但未经治疗的 AR 组与非 AR 组无显著差异。经过倾向评分匹配后,在 2-6 岁和 7-18 岁的 AR 患者中,使用 INCS 和/或 SGH 与 AE 发生率的显著降低相关(调整后的 HR:0.38、0.57 和 0.45)。

结论

一般来说,学龄前患者的 AE 发生率高于年长患者。对于 AR 合并哮喘患者,充分使用 INCS 和/或 SGH 治疗对于降低哮喘 AE 的发生率很重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验